Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. Post author:Sam Post published:December 18, 2017 Post category:BioPharma The FDA broke new ground today with a first-of-its-kind therapy for eye disease. Source: BioSpace You Might Also Like Booming Bay Area Biotechs' Huge Headache: Where to House Their Employees October 12, 2017 Nemaura Pharma Appoints As Director Of Strategic Alliances April 6, 2017 3 Biotechs That Could be Sweet M&A Targets for Big Pharma July 5, 2017
